Skip to main content



10-24-2017 | Sulfonylurea | News

First-line sulfonylureas may increase hypoglycemia risk in type 2 diabetes

Patients initiating treatment for type 2 diabetes with sulfonylureas are more than four times as likely to be hospitalized with hypoglycemia as those treated with metformin, population-based study data show.

09-13-2017 | Pioglitazone | EASD 2017 | News

TOSCA.IT: Similar long-term CV safety profile for pioglitazone, sulfonylurea

 The TOCSA.IT investigators have found no differences in cardiovascular disease outcomes between patients with type 2 diabetes taking pioglitazone versus sulfonylurea over nearly 5 years.

05-19-2017 | Sulfonylurea | News

Hypoglycemia associated with cardiovascular risk among sulfonylurea users

Patients with type 2 diabetes who experience hypoglycemia during sulfonylurea treatment are at greater risk for cardiovascular events than those who do not experience hypoglycemia, results of a US study suggest.

Read more

Related topics




Journal articles and book chapters

10-05-2017 | Hypoglycemia | Review | Article

A systematic approach for the prevention and reduction of hypoglycemia in hospitalized patients

This review highlights approaches to predict and prevent inpatient hypoglycemia focusing on the development of overlapping procedures that allow safe glycemic management to occur at all levels of the institution.

Cruz P, Blackburn MC, Tobin GS. Curr Diab Rep 2017;17:117. doi:10.1007/s11892-017-0934-8

09-08-2017 | Latent autoimmune diabetes of adulthood | Review | Article

Nature Reviews Endocrinology

Adult-onset autoimmune diabetes: Current knowledge and implications for management

Buzzetti et al. review the pathophysiology and clinical features of adult-onset autoimmune diabetes and highlight the similarities and differences of the condition with type 1 and type 2 diabetes.

Nat Rev Endocrinol 2017;13:674–686. doi:10.1038/nrendo.2017.99

Raffaella Buzzetti, Simona Zampetti, Ernesto Maddaloni

07-31-2017 | Prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

In this review, Chatterjee et al. discuss the various glucose-lowering and other pharmaceutical interventions that have been tested for diabetes prevention and their use in real world settings.

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017. doi:10.1007/s40256-017-0239-y

Case reports

04-26-2016 | Neonatal diabetes | Case report | Article

Not all diabetes in infants is type 1: A case report

The authors present their experience with a patient with permanent neonatal diabetes, initially misdiagnosed as type 1 diabetes, who was successfully transitioned to oral sulfonylurea therapy after 37 years of insulin dependence.

Arce KM & Pantalone KM. Diabetes Ther 2016; 7: 369–375. doi:10.1007/s13300-016-0171-1

image credits